ArticleJournal of thoracic disease2017
Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.
Article in Journal of thoracic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Systematic analysis of mistletoe prescriptions in clinical studies.Journal of cancer research and clinical oncology · 2023Pooled it
- Article
- A fermented Mistletoe (Viscum album L.) extract elicits markers characteristic for immunogenic cell death driven by endoplasmic reticulum stress in vitro.BMC complementary medicine and therapies · 2025Article
- Application of the CARE guideline as reporting standard in theCardiovascular diagnosis and therapy · 2021Article
- Rare diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: one case report and literature review.Translational cancer research · 2020Article
- Application of the CARE guideline as reporting standard in theJournal of gastrointestinal oncology · 2020Article
- Article
- Application of the CARE guideline as reporting standard in theTranslational lung cancer research · 2019Article
- Application of the CARE guideline as reporting standard in theTranslational andrology and urology · 2019Article
- Application of the CARE guideline as reporting standard in theGland surgery · 2019Article
- Application of the CARE guideline as reporting standard in theJournal of spine surgery (Hong Kong) · 2019Article
- Application of the CARE guideline as reporting standard in theTranslational cancer research · 2019Article
- Application of the CARE guideline as reporting standard in theAnnals of translational medicine · 2019Article
- Application of the CARE guideline as reporting standard in theTranslational pediatrics · 2019Article
- Article
- Application of the CARE guideline as reporting standard in theAME case reports · 2019Article
- Application of the CARE guideline as reporting standard in theStem cell investigation · 2019Article
- Application of the CARE guideline as reporting standard in theMediastinum (Hong Kong, China) · 2019Article
- Application of the CARE guideline as reporting standard in theTranslational gastroenterology and hepatology · 2019Article
- Long-Term Survival of a Patient with Recurrent Dedifferentiated High-Grade Liposarcoma of the Retroperitoneum Under Adjuvant Treatment withIntegrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) is a rare cancer with a dismal prognosis. Viscum album extracts (VAE) have strong immune stimulatory properties, cytotoxic effects, can downregulate cancer genes and inhibit angiogenesis. VAE are often used as an adjunct treatment in cancer patients but have rarely been investigated in MPM. Helleborus niger extracts (HNE) have been used in anticancer therapy since antiquity, and also show tumor specific cytotoxic effects. We present a case of a 64-year old woman with epithelioid MPM of the right chest with node involvement (T2N1M0, stage III). Deciding against the recommended radio-chemotherapy, surgery and pleurodesis, she opted for an integrative treatment approach and was treated with VAE and HNE. After 6 weeks' treatment, the pleural and nodal MPM manifestations were reduced by about 15%. Subsequent tumor growth was slow, and the patient remained in good health, enabling her to remain physically active until shortly before her death 56 months after the initial diagnosis. This is a rare case of an MPM patient not receiving any standard anticancer treatment; it still shows an extraordinary long survival and good performance status. We presume that VAE and HNE might had an impact on this clinically relevant outcome and therefore should be further investigated in MPM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.